Introduction
============

It is recognized that many physical illnesses may have a direct link to the appearance of depressive syndromes and many studies have documented a high rate of depression and anxiety among patients suffering from COPD ([@b44-copd-1-315]; [@b20-copd-1-315]; [@b40-copd-1-315]; [@b1-copd-1-315]; [@b10-copd-1-315]; [@b28-copd-1-315]). COPD is a severe treatment-resistant pulmonary disease with varying impact on the patient's general physical condition, functioning, and quality of life. It is assumed that a successful treatment of a co-morbid depression leads to improved quality of life and less restricted general functioning ([@b34-copd-1-315]). However, the evaluation of psychopathology in medical patients, eg, those with COPD, presents special problems. Almost all self-report and clinicians' rating scales for detecting depression is biased by a large number of items dealing with somatic symptoms. For example, the Hamilton Depression Scale (Ham-D) ([@b17-copd-1-315]; [@b18-copd-1-315]) has eight or nine items reflecting somatic complaints or changes in somatic functioning. Such items are also included in the official diagnostic criteria for depression, ie, ICD-10 ([@b43-copd-1-315]) and DSM-IV ([@b2-copd-1-315]). Therefore, it is difficult to decide when these somatic symptoms are secondary to depression and when they are a secondary to the somatic illness.

This review will focus on our knowledge about epidemiology, diagnostic procedures, treatment aspects, and quality of life in COPD patients with co-morbid depression. We will also summarize recent findings concerning how the interaction between depression and COPD may affect patients' survival.

Prevalence and co-morbidity
===========================

The prevalence of depressive symptoms in COPD patients varies considerably. Two recent reviews ([@b40-copd-1-315]; [@b28-copd-1-315]) found a prevalence of depression, ranging from 6% to 57%.

[@b40-copd-1-315] found a prevalence ranging from 6% to 42%. They emphasized that only 4 out of 34 studies had a control group ([@b27-copd-1-315]; [@b31-copd-1-315]; [@b19-copd-1-315]; [@b14-copd-1-315]). However, all four studies showed that the prevalence was higher in the study group, ie, the COPD patients, but the difference was statistically significant in two of the studies only ([@b27-copd-1-315]; [@b31-copd-1-315]).

[@b28-copd-1-315] pointed out that two of the latest prevalence studies identified clinically significant depressive symptoms in 42%--57% of COPD patients ([@b45-copd-1-315]; [@b24-copd-1-315]). The major co-morbidity studies are summarized in [Table 1](#t1-copd-1-315){ref-type="table"}.

There are many possible explanations for these differing results. Many studies are performed on small samples and are lacking control groups. The way the psychiatric diagnoses are obtained also varies. Some studies utilize established diagnostic criteria, other studies only use clinical assessments or self-reported symptoms. Most studies contain no formal data analysis and only simple descriptive statistics. Finally, differences in the objective characteristics and severity of COPD may contribute to the variations in prevalence figures.

In summary, the prevalence of depression is high in COPD patients, for both occurrence of "significant symptoms" and clinical depression. Although there are large variations in prevalence figures, the latest studies point out a prevalence of more than 40% ([@b45-copd-1-315]; [@b38-copd-1-315]).

Quality of life
===============

According to [@b27-copd-1-315], quality of life is concerned with the following four dimensions: emotional functioning, social-role functioning, activities of daily living (ADL), and recreational pastimes.

Compared with persons without physical illness, COPD patients have impaired quality of life ([@b27-copd-1-315]; [@b31-copd-1-315]; [@b48-copd-1-315]).

COPD patients with co-morbid depression have impaired quality of life compared with COPD patients without depression ([@b8-copd-1-315]; [@b48-copd-1-315]; [@b22-copd-1-315]; [@b4-copd-1-315]; [@b15-copd-1-315]; [@b46-copd-1-315]). [@b46-copd-1-315] also showed that COPD patients' quality of life was more correlated to the presence of depressive symptoms than to the severity of COPD as measured by FEV~1~. This phenomenon was also demonstrated by [@b22-copd-1-315]. In a different study 28 patients were followed over 4 years, but even though their physical condition got better because of aggressive medical treatment, no improvement in quality of life was shown ([@b41-copd-1-315]).

In spite of this, co-morbid depression does not seem to worsen the physical aspects of COPD ([@b26-copd-1-315]; [@b5-copd-1-315]). For example [@b26-copd-1-315] found no significant correlation between the level of depression or anxiety and the distance that the patient could walk in 12 minutes.

Diagnostic aspects
==================

Today, the ICD-10 and DSM-IV criteria for depression are the most common diagnostic tools. When it comes to depression in patients with severe somatic illness, the validity of the ICD-10 and DSM-IV criteria for depression may to a certain degree be questioned because it is difficult to decide when somatic symptoms are secondary to depression and when they are secondary to somatic illness. In fact, the ICD-10 has a general exclusion criterion that the depressive episode is not attributed to any organic cause, while the DSM-III-R/IV is less restrictive on the matter. Severe COPD could lead to somatic symptoms impossible to separate from depressive symptoms. [@b13-copd-1-315] has therefore suggested replacement of the somatic symptoms in the DSM-III-R/IV criteria with alternative non-somatic depressive symptoms, ie, replace change in appetite--weight with tearfulness--depressed appearance, sleep disturbances with social withdrawal, fatigue or loss of energy with brooding--pessimism, and diminished ability to think or concentrate with lack of reactivity to environmental events. These modifications have to some extent been validated ([@b32-copd-1-315]; [@b21-copd-1-315]) and may be they should be used when trying to identify depression in subjects with somatic illness. However, as long as there is no method for deciding whether the somatic symptoms are secondary to depression or COPD, the classification will be biased.

In a recent study, we tested the internal and external validity of the six-item Hamilton Depression subscale (HAM-D-6) in a sample of 49 COPD patients ([@b38-copd-1-315]). We found that HAM-D-6 could be used as a screening instrument for depression in COPD patients, ie, the sensitivity of the test was 0.91, the specificity was 0.88, the positive predictive value 0.87, and the negative predictive value was 0.91 when the cut-off score was set to 7 or more on HAM-D-6. The HAM-D-6 items are shown in [Table 2](#t2-copd-1-315){ref-type="table"}. If the HAM-D-6 total score is 10 or more, treatment with an antidepressant is often required.

Treatment of depression in COPD patients
========================================

Antidepressants
---------------

The tricyclic antidepressants (TCAs) have been tested in a few studies ([@b25-copd-1-315]; [@b35-copd-1-315]; [@b7-copd-1-315]). Although the results are contradictory, there is some evidence that TCAs are effective. [@b6-copd-1-315] studied 30 patients who completed a 12-week, randomized, controlled trial of nortriptyline. Nortriptyline was clearly superior to placebo for treatment of depression. Nortriptyline treatment was accompanied by marked improvements in anxiety, certain respiratory symptoms, overall physical comfort, and day-to-day function; placebo effects were negligible. Physiological measures reflecting pulmonary insufficiency were generally unaffected by treatment. It has also been shown that imipramine in combination with diazpam is effective ([@b35-copd-1-315]), while doxepine failed in a placebo-controlled trial ([@b25-copd-1-315]). [Table 3](#t3-copd-1-315){ref-type="table"} shows treatment information about imipramine and nortriptyline. Note that the doses of imipramine and nortriptyline are lower than in patients without co-morbid COPD, mainly because most COPD patients are elderly. Treating elderly patients with TCAs like imipramine and nortriptyline is not unproblematic due to an increased risk of severe side-effects. The decision to start a TCA treatment balances the documented efficacy and the increased risk of side-effects in elderly patients.

Little is known about the effectiveness of newer antidepressants like the selective serotonin reuptake inhibitors (SSRIs) but smaller studies and case reports suggests that SSRIs are well tolerated although the compliance may be poor ([@b30-copd-1-315]; [@b37-copd-1-315]; [@b47-copd-1-315]).

Benzodiazepines and other drugs
-------------------------------

Benzodiazepines have anxiolytic effect in COPD patients ([@b29-copd-1-315]), but may cause respiratory depression. Therefore, benzodiazepines should be considered only if other anxiolytic agents have failed.

Buspirone has been tested in COPD patients, but the results are not conclusive ([@b3-copd-1-315]; [@b36-copd-1-315]).

Non-pharmacological treatment
-----------------------------

In general the non-pharmocological treatment of depression in COPD is limited to patients with milder depression and here multidisciplinary pulmonary rehabilitation as well as cognitive-behavioral therapy (CBT) appears effective ([@b6-copd-1-315]).

CBT for this group of patients includes increasing the patients' body-awareness by exercises in relaxation and breathing. The cognitive elements of the treatment are aimed at identifying automatic thoughts and promote a more adaptive cognitive style. Graduated exposure and desensitizing is then attempted to reduce fears of symptoms as well as alleviating the panic reactions. [@b11-copd-1-315] found that six sessions of CBT resulted in sustained improvement in exercise tolerance in patients suffering from severe COPD and anxiety. In a recent randomized clinical trial ([@b23-copd-1-315]), a single 2-hour session of group CBT and weekly calls over 6 weeks reduced both depressed mood and anxiety. The effect was significantly better than in the control group (2-hour education and weekly calls). There were no improvements in physical functioning in either group.

Pulmonary rehabilitation programs have also been described for COPD patients for co-morbid anxiety and depression. By means of progressive exercise, training of respiratory function, and psycho-education, patients obtained better exercise tolerance, less dyspnea, and better quality of life ([@b33-copd-1-315]; [@b12-copd-1-315]; [@b42-copd-1-315]; [@b9-copd-1-315]; [@b16-copd-1-315]).

Does depression affect the long-term outcome in COPD patients?
==============================================================

Few studies have examined the long-term outcome of depressed COPD patients. Yet we recently published a study focusing on the survival in COPD patients ([@b39-copd-1-315]). We found that co-morbid depression significantly reduced the mortality risk at follow-up. The impact of depression remained after control for FEV~1~, the only multivariate significant predictor of mortality in the data set (hazard ratio, 0.27; 95% confidence interval, 0.09--0.84; p=0.024). The cumulative mortality for depressed and non-depressed COPD patients is shown in [Figure 1](#f1-copd-1-315){ref-type="fig"}. We concluded that depression appears to be an independent protector for mortality, although we have no clues about the underlying mechanism. However, the study included only 49 patients and it should be replicated in a larger sample.

Conclusion
==========

Depression is very common in COPD patients. Around 40% are affected by severe depressive symptoms or clinical depressions. It is not easy to diagnose depression in COPD patients because of the overlapping symptoms between COPD and depression. However, the six-item Hamilton Depression Subscale (HAM-D-6) appears to be a useful screening tool. Quality of life is strongly impaired in COPD patients and patients' quality of life emerges to be more correlated with the presence of depressive symptoms than with the severity of COPD. Nortriptyline and imipramine are effective in the treatment of depression, but little is known about the usefulness of newer antidepressants. In patients with milder depressionm, pulmonary rehabilitation as well as cognitive-behavioral therapy seem effective. Little is known about the long-term outcome in COPD patients with co-morbid depression. Preliminary data suggest that co-morbid depression may be an independent protector for mortality.

Much more research is needed concerning epidemiology, psychopathology, quality of life, treatment, and long-term outcome.

The key points of this review are shown in [Table 3](#t3-copd-1-315){ref-type="table"}.

![Cumulative mortality for depressed and non-depressed COPD patients. Reprinted from [@b39-copd-1-315]. Depression and chronic obstructive pulmonary disease (COPD). Impact on survival. *Acta Psychiatr Scand*, 111:320--3. Copyright © 2005 with permission from Blackwell Publishing.](copd-1-315f1){#f1-copd-1-315}

###### 

Summary of co-morbidity studies: Prevalence of psychiatric co-morbidity in COPD patients

  Author              Sample/control group                                            Psychiatric assessment methods Findings             
  ------------------- --------------------------------------------------------------- --------------------------------------------------- -------------------------------------------------------------------------------
  [@b27-copd-1-315]   203 COPD, nocturnal oxygen treatment 73 healthy controls (HC)   Self-report: MMPIPOMS, SIP                          Depression 42% in COPDvs 9% in
                                                                                                                                          HC
  [@b31-copd-1-315]   985 COPD outpatients                                            Self report: POMS, SIP                              No prevalence figures.
                      25 HC                                                                                                               POMS anxiety and depression score significantly higher in COPD group
  [@b44-copd-1-315]   50 COPD inpatients with exacerbation                            Psychiatric interview: DSM-III diagnoses            Panic anxiety 24%
                                                                                                                                          Generalized anxiety 10%
                                                                                                                                          Depression 12%
  [@b20-copd-1-315]   50 COPD outpatients                                             Psychiatric interview: DSM-III diagnoses            Anxiety disorders 16%
                                                                                                                                          Mood disorders 8%
  [@b19-copd-1-315]   82 COPD community sample                                        Self-report: Zung Depression Scale                  Depression, men 26% vs 18%
                      246 HC                                                                                                              Depression, women 33% vs 20%,
                                                                                                                                          Differences non-significant
  [@b14-copd-1-315]   68 COPD in- and outpatients                                     Self-report: HADS                                   Depression 7% vs 1%
                      89 HC                                                                                                               Anxiety 13% vs 6%
                                                                                                                                          Differences significant
  [@b45-copd-1-315]   137 COPD outpatients                                            Psychiatric interview and self-report: MADRS        Clinical depression in 42% 2/3 of these patients moderately depressed (MADRS)
                                                                                      Geriatric Mental Health Scale                       
  [@b10-copd-1-315]   79 COPD inpatients                                              Self-report:HADS                                    Depression 28%
                                                                                                                                          Anxiety 50%
  [@b24-copd-1-315]   109 COPD, home care                                             Self-report: SF-36                                  Depressive symptoms 57%
                                                                                      GDS                                                 
  [@b1-copd-1-315]    30 COPD outpatients                                             Self report and interview: GHQ-30                   Depression 16.7% anxiety 10% in COPD group
                      30 hypertensive patients                                                                                            
                      30 HC                                                           PSE                                                 Significantly less in control groups
  [@b4-copd-1-315]    38 COPD inpatients 120 tuberculosis patients                    Self report: GHQ-12                                 Depression and/or anxiety 47.3%
                                                                                                                                          Prevalence 19%--26% in control group
                                                                                                                                          Differences significant
  [@b38-copd-1-315]   49 COPD outpatients                                             Psychiatric interview: ICD-10 diagnoses             Major depression 33%
                                                                                      Hamilton Rating Scales for anxiety and depression   Mild depression 14%

**Abbreviations**: GDS, Geriatric Depression Scale; GHQ, General Health Questioner; HADS, Hospital Anxiety and Depression Scale; HC, healthy controls; MADRS, Montgomery-Asberg Rating Scale; MMPI, Minnesota Multiphasic Personality Intervention; POMS, Profile of Mood States; SIP, Sickness Impact Profile.

###### 

The six-item Hamilton Depression subscale (HAM-D-6)

  ----------------------------------------------------------------------------------------
  Depressed moodGuilt feelingsWork and interestRetardationPsychic anxietyGeneral somatic
  ----------------------------------------------------------------------------------------

###### 

Treatment information about the tricyclic antidepressants (TCAs) imipramine and nortriptyline: the decision to start a TCA treatment balances the documented efficacy and the increased risk of side-effects in elderly patients

  Effect                                 Better than placebo in randomized controlled trials
  -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Dose in elderly patients               Imipramine: 50--100 mg/day
                                         Nortriptyline: 25--75 mg/day
                                         Start low -- go slow!
  Recommended plasma                     Imipramine (plus desipramine): 175--350 ng/ml
  levels at steady state                 Nortriptyline: 50--150 ng/ml
  Examples of common side-effects        Orthostatic hypotension (less common with nortriptyline), dizziness, tachycardia, dry mouth, blurred vision, disturbance of accommodation, constipation, and drowsiness
  Examples of less common side-effects   Arrhythmias, heart block, confusional states, seizures, urinary retention, paralytic ileus, drug fever, skin rash, bone marrow depression, altered liver function, hypomania, and falls. Increased mortality in patients with ischemic heart disease. Pre-existing heart block gets worse during treatment
  Pre-treatment examinations             Physical examination
                                         Measurement of orthostatic hypotension
                                         ECGBlood tests including liver enzymes

[Table 3](#t3-copd-1-315){ref-type="table"}: Key points

Around 40% of all COPD patients have severe depressive symptoms or clinical depressionThe six-item Hamilton Depression Subscale seems to be a useful screening toolQuality of life is strongly impaired in COPD patients and is more correlated with the presence of depressive symptoms than to the severity of COPDNortriptyline, imipramine, pulmonary rehabilitation. and cognitive-behavioral therapy are effective treatment optionsPreliminary data suggest that co-morbid depression may be an independent protector for mortalityMuch more research is needed in this field
